Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: Impact of pretransplantation and posttransplantation factors on outcome

Journal of Clinical Oncology

Volumn 19, Issue 14, 2001, Pages 3340-3349

  Michallet, M ^a   Bilger, K ^a   Garban, F ^a   Attal, M ^a   Huyn, A ^a   Blaise, D ^a   Milpied, N ^a   Moreau, P ^a   Bordigoni, P ^a   Kuentz, M ^a   Sadoun, A ^a   Cahn, J Y ^a   Socie G ^a   Thomas, X ^a   Arnaud, P ^a   Raus, N ^a   Lheritier V ^a   Pigneux, A ^a   Boiron, J M ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; STEROID; THYMOCYTE ANTIBODY;

ACUTE LEUKEMIA; ADULT; ALLOGRAFT; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CHIMERA; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOMA; PRIORITY JOURNAL; PROPHYLAXIS; SOLID TUMOR; STEM CELL; STEROID THERAPY; TREATMENT OUTCOME;

EID: 0035879230     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.14.3340     Document Type: Article

References (48)

1. How does bone marrow transplantation cure leukemia?
2. Aplastic anaemia
3. Bone marrow transplantation for patients with chronic myeloid leukemia
4. Modification of regimen-related cellular toxicity
5. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomised trial of two irradiation regimens
6. Treatment of murine leukemia with x-rays and homologous bone marrow
7. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts
8. Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation
9. Bone marrow for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T cell depletion
10. T cell depletion of HLA identical transplants in leukemia
11. Impact of T-cell depletion on outcome of allogeneic bone marrow transplantation for standard-risk leukaemias
12. Allogeneic marrow transplantation from multiple myeloma: An analysis of risk factors in outcome
13. Graft versus leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia
14. Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies
15. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation
16. Graft-versus-myeloma effect: Proof of principle
17. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse
18. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukaemia responses from graft-versus-host disease
19. Donor leukocyte infusions for chronic myeloid leukaemia in relapse after allogeneic bone marrow transplantation
20. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukaemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose
21. Reinventing bone marrow transplantation: Reducing toxicity using non-myeloablative, preparative regimens and induction of graft-versus-malignancy
22. Non-myeloablative stem cell transplants
23. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
24. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
25. Non-myeloablative preparative regimens: Experimental data and clinical practice
26. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematologic diseases
27. Mixed lymphohaematopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone marrow transplantation
28. Engraftment kinetics after non-myeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses
29. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias
30. Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect
31. Non parametric estimation from incomplete observations
32. A review and critique of some models used in competing risk analysis
33. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: Part II: Analysis and examples
34. Regression models and life-tables
35. Non-myeloablative T-cell depleted allogeneic peripheral blood stem cell transplantation for patients with chronic granulomatous disease
36. Well tolerated non-myeloablative fludarabine-based protocols for the treatment of malignant and non-malignant disorders with allogeneic bone marrow or blood stem cell transplantation
37. Melphalan and purine analog containing preparative regimens: Less intensive conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
38. Allogeneic transplantation for leukaemia in patients older than 60 years: Age should not exclude treatment with non-myeloablative regimens
39. Non-toxicity and transplant related mortality (TRM) following non-myeloablative allogeneic peripheral blood stem cell transplantation for malignant disease
40. Outpatient allografting with minimally myelosuppressive, immunosuppressive conditioning of low dose TB1 and postgrafting (CSP) and mycophenolate mofetil (MMF)
41. A non-myeloablative regimen for allografting high risk patients: Low toxicity, stable engraftment without GVHD, disease control and potential for GVL with adoptive immunotherapy
42. Transplant-lite using fludarabine-cyclophosphamide (FC) and allogeneic stem cell transplant (AloSCT) for low grade lymphoma (LGL)
43. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia
44. Intrathymic deletion of alloreactive T cells in mixed bone marrow chimeras prepared with a non-myeloablative conditioning regimen
45. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkey
46. Engraftment of T-depleted allogeneic peripheral blood stem cells using a non-myeloablative conditioning regimen
47. Hematopoietic stem cell transplants (HSCT) from HLA matched and 1 allele mismatched unrelated donors using a non-myeloablative regimen
48. Matched unrelated bone marrow transplantation using a non-myeloablative conditioning regimen